Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris’ New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex...
-
TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
-
Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials
-
AtaiBeckley today announced its addition to the S&P Total Market Index, the S&P Completion Index and CRSP® U.S. benchmark indices, effective March 2
-
Claret Capital Partners, Europe's largest independent growth debt fund manager has made an investment, through its Fund IV, of up to EUR 28m
-
Aligned with FDA on dual-trial design Phase 3 program that aims to demonstrate robust efficacy and long-term safety and that allows for flexible dosingPhase 3 program initiation remains on track for...
-
Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles BOSTON, Feb. 26, 2026 (GLOBE...
-
Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files...
-
CMMB CEO Dr. Adi Mor will present at Oppenheimer's virtual 36th Annual Life Sciences Healthcare Conference on Feb. 26 at 8:00 am ET.
-
Aicuris today announced positive results from its pivotal Phase 3 trial evaluating pritelivir in immunocompromised patients with refractory HSV